AbbVie (ABBV)
(Real Time Quote from BATS)
$160.52 USD
+0.90 (0.56%)
Updated Apr 29, 2024 03:36 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
ABBV 160.52 +0.90(0.56%)
Will ABBV be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABBV
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
PCE/Core PCE Numbers Came In Line With Expectations
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses
AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
Other News for ABBV
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
AbbVie price target lowered by $15 at BMO Capital, here's why
Novo Nordisk: Growth Is Still A Better Choice
AbbVie price target lowered by $5 at Morgan Stanley, here's why